Skip to main content
PMC home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2002 Oct;110(Suppl 5):883–886. doi: 10.1289/ehp.02110s5883

Pathology related to chronic arsenic exposure.

Jose A Centeno 1, Florabel G Mullick 1, Leonor Martinez 1, Norbert P Page 1, Herman Gibb 1, David Longfellow 1, Claudia Thompson 1, Elena R Ladich 1
PMCID: PMC1241266  PMID: 12426152

Abstract

Millions now suffer the effects of chronic arseniasis related to environmental arsenic exposure. The biological mechanisms responsible for arsenic-induced toxicity and especially chronic effects, including cancer, are not well known. The U.S. Armed Forces Institute of Pathology (AFIP) is participating in an international research effort to improve this understanding by the development of the International Tissue and Tumor Repository for Chronic Arsenosis (ITTRCA). The ITTRCA obtains, archives, and makes available for research purposes, tissues from subjects exposed to arsenic. We provide here a short overview of arsenic-induced pathology, briefly describe arsenic-induced lesions in the skin and liver, and present five case reports from the ITTRCA. Arsenic-induced skin pathology includes hyperkeratosis, pigmentation changes, Bowen disease, squamous cell carcinoma, and basal cell carcinomas. A unique spectrum of skin lesions, known as arsenical keratosis, is rather characteristic of chronic arseniasis. Bowen disease, or squamous cell carcinoma in situ of the skin, has been well documented as a consequence of arsenical exposure. A spectrum of liver lesions has also been attributed to chronic arseniasis. Of these, hepatocellular carcinoma, angiosarcoma, cirrhosis, and hepatoportal sclerosis have been associated with arsenic exposure. We present case reports that relate to these health conditions, namely, squamous cell carcinoma, basal cell carcinoma, and Bowen disease of the skin and hepatocellular carcinoma and angiosarcoma of the liver. Four patients had been treated with arsenical medications for such conditions as asthma, psoriasis, and syphilis, and one case occurred in a boy chronically exposed to arsenic in drinking water.

Full Text

The Full Text of this article is available as a PDF (242.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biggs M. L., Haque R., Moore L., Smith A., Ferreccio C., Hopenhayn-Rich C. Arsenic-laced water in Chile. Science. 1998 Aug 7;281(5378):785–785. doi: 10.1126/science.281.5378.783g. [DOI] [PubMed] [Google Scholar]
  2. Chen C. J., Chiou H. Y., Chiang M. H., Lin L. J., Tai T. Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504–510. doi: 10.1161/01.atv.16.4.504. [DOI] [PubMed] [Google Scholar]
  3. Chen C. J., Hsueh Y. M., Lai M. S., Shyu M. P., Chen S. Y., Wu M. M., Kuo T. L., Tai T. Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995 Jan;25(1):53–60. [PubMed] [Google Scholar]
  4. Chen C. J., Wang C. J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 1990 Sep 1;50(17):5470–5474. [PubMed] [Google Scholar]
  5. Datta D. V., Mitra S. K., Chhuttani P. N., Chakravarti R. N. Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India. Gut. 1979 May;20(5):378–384. doi: 10.1136/gut.20.5.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dueñas C., Pérez-Alvarez J. C., Busteros J. I., Sáez-Royuela F., Martin-Lorente J. L., Yuguero L., López-Morante A. Idiopathic portal hypertension and angiosarcoma associated with arsenical salts therapy. J Clin Gastroenterol. 1998 Jun;26(4):303–305. doi: 10.1097/00004836-199806000-00019. [DOI] [PubMed] [Google Scholar]
  7. Falk H., Caldwell G. G., Ishak K. G., Thomas L. B., Popper H. Arsenic-related hepatic angiosarcoma. Am J Ind Med. 1981;2(1):43–50. doi: 10.1002/ajim.4700020108. [DOI] [PubMed] [Google Scholar]
  8. Hood R. D., Thacker G. T., Patterson B. L. Effects in the mouse and rat of prenatal exposure to arsenic. Environ Health Perspect. 1977 Aug;19:219–222. doi: 10.1289/ehp.7719219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hopenhayn-Rich C., Biggs M. L., Fuchs A., Bergoglio R., Tello E. E., Nicolli H., Smith A. H. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996 Mar;7(2):117–124. doi: 10.1097/00001648-199603000-00003. [DOI] [PubMed] [Google Scholar]
  10. Hopenhayn-Rich C., Biggs M. L., Smith A. H. Lung and kidney cancer mortality associated with arsenic in drinking water in Córdoba, Argentina. Int J Epidemiol. 1998 Aug;27(4):561–569. doi: 10.1093/ije/27.4.561. [DOI] [PubMed] [Google Scholar]
  11. Lai M. S., Hsueh Y. M., Chen C. J., Shyu M. P., Chen S. Y., Kuo T. L., Wu M. M., Tai T. Y. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol. 1994 Mar 1;139(5):484–492. doi: 10.1093/oxfordjournals.aje.a117031. [DOI] [PubMed] [Google Scholar]
  12. Léonard A., Lauwerys R. R. Carcinogenicity, teratogenicity and mutagenicity of arsenic. Mutat Res. 1980 Jan;75(1):49–62. doi: 10.1016/0165-1110(80)90027-5. [DOI] [PubMed] [Google Scholar]
  13. Maloney M. E. Arsenic in Dermatology. Dermatol Surg. 1996 Mar;22(3):301–304. doi: 10.1111/j.1524-4725.1996.tb00322.x. [DOI] [PubMed] [Google Scholar]
  14. Neshiwat L. F., Friedland M. L., Schorr-Lesnick B., Feldman S., Glucksman W. J., Russo R. D., Jr Hepatic angiosarcoma. Am J Med. 1992 Aug;93(2):219–222. doi: 10.1016/0002-9343(92)90054-f. [DOI] [PubMed] [Google Scholar]
  15. Nevens F., Fevery J., Van Steenbergen W., Sciot R., Desmet V., De Groote J. Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol. 1990 Jul;11(1):80–85. doi: 10.1016/0168-8278(90)90276-w. [DOI] [PubMed] [Google Scholar]
  16. Nordström S., Beckman L., Nordenson I. Occupational and environmental risks in and around a smelter in northern Sweden. III. Frequencies of spontaneous abortion. Hereditas. 1978;88(1):51–54. doi: 10.1111/j.1601-5223.1978.tb01602.x. [DOI] [PubMed] [Google Scholar]
  17. Regelson W., Kim U., Ospina J., Holland J. F. Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer. 1968 Mar;21(3):514–522. doi: 10.1002/1097-0142(196803)21:3<514::aid-cncr2820210323>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  18. Tsai S. M., Wang T. N., Ko Y. C. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999 May-Jun;54(3):186–193. doi: 10.1080/00039899909602258. [DOI] [PubMed] [Google Scholar]
  19. Tsai S. M., Wang T. N., Ko Y. C. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health. 1999 May-Jun;54(3):186–193. doi: 10.1080/00039899909602258. [DOI] [PubMed] [Google Scholar]
  20. Wu M. M., Kuo T. L., Hwang Y. H., Chen C. J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989 Dec;130(6):1123–1132. doi: 10.1093/oxfordjournals.aje.a115439. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES